Fecal Microbiota Transplant in a Pre-Clinical Model of Type 2 Diabetes Mellitus, Obesity and Diabetic Kidney Disease

Autor(es):Mostrar menos -

Bastos, Rosana M. C. ; Simplicio-Filho, Antonio ; Savio-Silva, Christian ; Oliveira, Luiz Felipe, V ; Cruz, Giuliano N. F. ; Sousa, Eliza H. ; Noronha, Irene L. ; Mangueira, Cristovao L. P. ; Quaglierini-Ribeiro, Heloisa ; Josefi-Rocha, Gleice R. ; Rangel, Erika B.

• Tipo de documento: Artigo Científico
• Fonte: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES; v. 23, n. 7, p. 20-pg., 2022-04-01.

Resumo

Diabetes mellitus (DM) burden encompasses diabetic kidney disease (DKD), the leading cause of end-stage renal disease worldwide. Despite compelling evidence indicating that pharmacological intervention curtails DKD progression, the search for non-pharmacological strategies can identify novel targets for drug development against metabolic diseases. One of those emergent strategies comprises the modulation of the intestinal microbiota through fecal transplant from healthy donors. This study sought to investigate the benefits of fecal microbiota transplant (FMT) on functional and morphological parameters in a preclinical model of type 2 DM, obesity, and DKD using BTBRob/ob mice. These animals develop hyperglycemia and albuminuria in a time-dependent manner, mimicking DKD in humans. Our main findings unveiled that FMT prevented body weight gain, reduced albuminuria and tumor necrosis factor-alpha (TNF-alpha) levels within the ileum and ascending colon, and potentially ameliorated insulin resistance in BTBRob/ob mice. Intestinal structural integrity was maintained. Notably, FMT was associated with the abundance of the succinate-consuming Odoribacteraceae bacteria family throughout the intestine. Collectively, our data pointed out the safety and efficacy of FMT in a preclinical model of type 2 DM, obesity, and DKD. These findings provide a basis for translational research on intestinal microbiota modulation and testing its therapeutic potential combined with current treatment for DM. (AU)

• Processo FAPESP: 13/19560-6 - As células c-kit positivas são células-tronco específicas do rim e apresentam capacidade regenerativa
• Beneficiário: Érika Bevilaqua Rangel
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 17/23195-2 - Terapia com células-tronco mesenquimais como abordagem terapêutica para reduzir a progressão das lesões renais agudas e crônicas e para modular in vivo as células-tronco c-Kit específicas do tecido renal
• Beneficiário: Érika Bevilaqua Rangel
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 16/26263-6 - Desenvolvimento de uma terapia baseada em células-troncos mesenquimais transfectadas com plasmídeos contendo os genes do HGF e Klotho conjugados a nanopartículas visando o tratamento em modelo animal de Nefropatia Diabética
• Beneficiário: Eliza Higuti Sousa
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 17/18072-9 - Alterações da dinâmica mitocondrial em células glomerulares mesangiais expostas à hiperglicemia e a regeneração pelas células tronco mesenquimais
• Beneficiário: Christian Sávio Silva
• Modalidade de apoio: Bolsas no Brasil - Mestrado